Internal: Archive Archives - Page 2091 of 2840

More

Profit warning hammers Converium at the bourse

This content was published on Jul 20, 2004 The company said it might have to ask shareholders for cash to replenish funds drained by rising claims in the United States. Converium said in a statement that it planned to raise up to $400 million (SFr491.8 million) to cover US casualty claims (third party liability) and was exploring other options for maintaining a strong…

More

Helping Haiti towards a better future

This content was published on Jul 20, 2004 Donor nations pledged $1.1 billion (SFr1.37 billion) to help rebuild a country which has suffered from 15 years of political and economic instability. The International Donor Conference on Haiti, which wrapped up in Washington on Tuesday, discussed the country’s short- and medium-term development needs. Haiti has been facing a political and humanitarian crisis since last…

More

Novartis boosts profit and market share

This content was published on Jul 20, 2004 Group sales reached $13.6 billion – up by 14 per cent – fuelled by pharmaceuticals growth and increased sales in its Consumer Health division. Pharma sales, which climbed 17 per cent, were driven by demand for the hypertension treatment Diovan and the leukaemia drug Gleevec/Glivec. “Our strategy has delivered strong organic sales growth and productivity…

More

Timber users take a sustainable approach to wood

This content was published on Jul 19, 2004 In future, Swiss door producers will only use specially labelled wood from forests which are sustainably managed. The accord was signed in Bern on Monday between the Swiss Door Manufacturers Association, and Greenpeace Switzerland and WWF Switzerland. The Swiss Door Manufacturers Association is the largest importer of tropical timber in Switzerland accounting for 30 per…

More

Roche sells non-prescription activities to Bayer

This content was published on Jul 19, 2004 Roche said the sale of its non-prescription unit would allow the group to focus on its core pharmaceuticals and diagnostics businesses. Under the terms of the deal, announced on Monday, Basel-based Roche will also sell to Bayer its 50 per cent stake in the companies’ joint venture in the United States. However, Roche will not…

More

Frankfurt eyes link-up with Swiss bourse

This content was published on Jul 19, 2004 The SWX said both parties planned to hold negotiations but would not comment on speculation about a possible merger of the two exchanges. “I can confirm that we have received a letter to enter talks about a closer cooperation, but I can’t comment further on the contents,” said SWX spokesman Werner Vogt. A spokesman for…

More

Swiss bourse spurns Frankfurt’s advances

This content was published on Jul 19, 2004 The SWX’s decision comes in response to an invitation from Deutsche Börse in July to start talks. The SWX ruled out for the time being any sale, merger or total integration of the group into another exchange, said a statement following a board meeting on Friday. The board added that, as an “independent organisation”, it…

More

Roche sails back into the black

This content was published on Jul 19, 2004 The company said its growth had “significantly” outpaced the global market, with total sales up by six per cent to SFr31.2 billion. And Roche said it expected to grow faster than its peers again this year. “We are pleased to report that we achieved our ambitious goals in 2003. Together our core pharmaceuticals and diagnostics…

More

Cloud hangs over Basel’s chemical industry

This content was published on Jul 19, 2004 The study makes gloomy reading for workers in Switzerland’s chemicals capital, Basel. The latest European Chemical Industry Council (CEFIC) report says that although the continent’s chemical and pharmaceutical companies may continue to thrive, large numbers of jobs are likely to be lost, as companies relocate operations to Asia to take advantage of lower production costs.…

Internal: Archive

Popular Stories

Most Discussed

Internal: Archive

More

Profit warning halves Converium’s market value

More

Profit warning hammers Converium at the bourse

More

Helping Haiti towards a better future

More

Novartis boosts profit and market share

More

Timber users take a sustainable approach to wood

More

Roche sells non-prescription activities to Bayer

More

Frankfurt eyes link-up with Swiss bourse

More

Swiss bourse spurns Frankfurt’s advances

More

Roche sails back into the black

More

Cloud hangs over Basel’s chemical industry

Popular Stories

Most Discussed